Thomas G. Kramer
Thank you, Niccolo, Jordan and Frank. It has been truly an exciting quarter on the commercial front, and our financials are no exception. Let's walk through this quarter's financial results in more detail. As Niccolo mentioned, we had a fantastic quarter, recognizing revenue of $20.7 million, beating the high end of our guidance by 15%. In addition, we are making new investments to accelerate our road map as well as entering new segments of the market, and we expect to continue to invest in the ecosystems that support our customers. Accordingly, we saw an adjusted EBITDA loss for the second quarter of $36.5 million compared to a $23.7 million loss in the prior-year period. To understand the key drivers behind that number, let's turn to our expenses. Total operating costs for the second quarter were $181.3 million, up 201% from $60.3 million in the prior-year period, but within our plan for the year. To break this down further, our research and development costs for the second quarter were $103.4 million, up 231% from $31.2 million in the prior-year period. Recall that we are investing heavily in R&D and growing our R&D headcount to support our road map and customer commitments. Our sales and marketing costs in the second quarter were $10.9 million, up 77% from $6.1 million in the prior-year period. This increase was due to us growing both our marketing and sales teams as we continue investing in our commercial efforts. Our general and administrative costs in the second quarter were $48.1 million, up 269% from $13.1 million in the prior-year period. These increases were primarily driven by an increase in professional services and payroll-related expenses. All of this resulted in a net loss of $177.5 million in the second quarter compared to a $37.6 million net loss in the prior-year period. Accounting for warrants can be confusing, so we have always pointed out the impact they have on our results. This Q2 loss includes a noncash loss of $39.6 million for the second quarter related to the fair value of our warrant liabilities. This is a pure accounting artifact that is not representative of the operating performance of our business. These results also include growth in stock-based compensation expense related to our headcount growth, which was $99.2 million for the second quarter compared to $21 million in the prior-year period. This elevated stock-based compensation expense was due primarily to incentives issued to newly acquired and hired employees. Turning now to our balance sheet. Cash, cash equivalents and investments as of June 30, 2025, were $656.8 million. As we announced previously, in July, we raised $1 billion in an equity offering priced at a 25% premium above our closing price for the prior trading session. This investment, to our knowledge, is the largest investment by a single investor into quantum computing and networking, and we are honored to be the recipient. The equity offering also included 7-year warrants at $99.88 per share, a strong indication of confidence in IonQ's longer-term prospects. Our pro forma cash balance as of July 9, 2025, was $1.6 billion, making IonQ the most well-capitalized pure-play quantum provider in the market today. Continuing now to our financial outlook. We are increasing our revenue guidance for the full year 2025 to be between $82 million and $100 million and expect revenue for the third quarter to be between $25 million and $29 million. Last quarter, we projected an adjusted EBITDA loss of $162 million for the full year 2025. Pending the close of the Oxford Ionics acquisition, we anticipate that integration and our continued investments into to accelerate our road map will result in an increase to our cost base for the year. We envision this will widen our adjusted EBITDA loss up to 30% or a total of $211 million. Now back to you, Niccolo.